Uncategorized

Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity Ad Data in Peer-reviewed Neurology and Therapy Journal

Uncategorized /

Eisai Co., Ltd. announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta protofibril* antibody lecanemab in people living with mild cognitive impairment due to Alzheimer’s disease and mild AD using data from the Phase 3 clinical study, Clarity AD by applying a validated disease simulation model.

Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity Ad Data in Peer-reviewed Neurology and Therapy Journal Read More »

AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab’s Significant Impact on Prurigo Nodularis

Uncategorized /

Galderma, the leading company solely dedicated to advancing the future of dermatology, premiered the positive phase III results from the OLYMPIA 2 trial evaluating the efficacy, safety, pharmacokinetics and immunogenicity of nemolizumab compared with placebo in adult patients with prurigo nodularis.

AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab’s Significant Impact on Prurigo Nodularis Read More »

Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo

Uncategorized /

Incyte announced new 104-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Opzelura® cream 1.5% in patients 12 years of age and older with nonsegmental vitiligo, a chronic autoimmune disease characterized by depigmentation of skin.

Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo Read More »

Pivotal Clinical SAHARA Study Shows Candesant Biomedical’s Investigational Sweat Control Patch Significantly Reduces Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

Uncategorized /

Candesant Biomedical announced findings from its pivotal clinical study of its investigational sweat control patch, the first three-minute patch for the significant reduction of excessive underarm sweating in patients with primary axillary hyperhidrosis.

Pivotal Clinical SAHARA Study Shows Candesant Biomedical’s Investigational Sweat Control Patch Significantly Reduces Primary Axillary Hyperhidrosis (Excessive Underarm Sweating) Read More »

Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study

Uncategorized /

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, shared new performance data from a novel, multi-center, independent cohort demonstrating how the independent risk-stratification of DecisionDx®-SCC test) can significantly improve metastatic risk predictions by complementing current staging systems.

Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study Read More »

Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis

Uncategorized /

Takeda announced positive results from a Phase 2b clinical trial of TAK-279, a highly selective, oral allosteric tyrosine kinase 2 inhibitor, in patients with moderate-to-severe plaque psoriasis.

Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis Read More »

Scroll to Top